Hyperkalemia — Causes and Management

• Impaired Renal Potassium Excretion (Most Common Mechanism): The kidneys normally excrete 90-95% of dietary potassium, primarily through principal cells in the cortical collecting duct via the epithelial sodium channel (ENaC) and renal outer medullary potassium (ROMK) channel. Renal potassium secretion is driven by three factors: (1) the electrical gradient created by sodium reabsorption (which generates a negative luminal potential favoring potassium secretion), (2) aldosterone signaling, which upregulates ENaC and Na-K-ATPase expression, and (3) distal potassium delivery. Conditions reducing glomerular filtration rate (GFR) below 15 mL/min, aldosterone deficiency or resistance (as in type 4 renal tubular acidosis, or from ACE inhibitors/angiotensin receptor blockers [ARBs]), and NSAIDs (which reduce renal perfusion and aldosterone synthesis) all impair this critical excretory pathway. Hyperkalemia in CKD typically emerges when remaining nephrons become overwhelmed by potassium load, though adaptive mechanisms (increased intestinal secretion, increased urinary concentration) partially compensate until advanced renal failure.

• Transcellular Potassium Shift (Acute Movement from Intracellular to Extracellular Space): Under normal conditions, the Na-K-ATPase pump maintains a 30:1 potassium gradient (140 mEq/L intracellular vs. 5 mEq/L extracellular), consuming ~20% of resting cellular ATP. Factors disrupting this gradient cause acute hyperkalemia even in patients with normal renal function. Acidosis (particularly from mineral acids) decreases hydrogen ion secretion in renal collecting ducts, which normally drives potassium secretion; simultaneously, extracellular acidosis impairs the Na-K-ATPase pump directly, causing potassium to shift out of cells—each 0.1 unit decrease in pH raises serum potassium by ~0.6 mEq/L. Beta-adrenergic antagonists (propranolol, atenolol, but not beta-1 selective agents at therapeutic doses) block β2-mediated cellular potassium uptake, unmasking an acute hyperkalemic effect particularly problematic in AKI or following exercise. Insulin deficiency (as in diabetic ketoacidosis [DKA]) removes the primary anabolic signal for potassium entry; the profound hyperkalemia in DKA results from both transcellular shift and total body depletion. Hyperosmolality (from hyperglycemia, hypertonic saline, or mannitol) creates osmotic gradients that draw water out of cells, concentrating intracellular potassium and promoting passive diffusion into the extracellular space. Cell death from any cause (hemolysis, rhabdomyolysis, tumor lysis syndrome, massive myocardial infarction) releases massive amounts of intracellular potassium; this mechanism can produce potassium levels >7-8 mEq/L acutely.

• Increased Potassium Intake: Excessive dietary potassium rarely causes hyperkalemia in patients with normal renal function and aldosterone responsiveness, as healthy kidneys can excrete 400+ mEq/day. However, in patients with CKD, RAAS blockade, or aldosterone deficiency, even modest increases in dietary potassium become problematic. Potassium supplementation (prescribed or from salt substitutes containing KCl), potassium-rich foods (bananas, dried fruits, nuts), and transfusion of stored blood products (potassium leaches from RBCs during storage) all contribute to total body potassium excess. In the extreme, potassium-containing antibiotics (penicillin G potassium), potassium phosphate supplements, and low-sodium foods marketed for CKD patients represent insidious sources.

• Cardiac Manifestations Result from Altered Resting Membrane Potential: The cardiac action potential is exquisitely sensitive to serum potassium concentration. Elevated extracellular potassium depolarizes the resting membrane potential, bringing it closer to the threshold for action potential generation. This causes three characteristic ECG changes in sequence: (1) peaked T waves (earliest finding, at K+ ~5.5-6.5 mEq/L) result from shortened ventricular repolarization; (2) PR prolongation and QRS widening (at K+ ~6.5-7.5 mEq/L) reflect slowed atrial and ventricular conduction as partial depolarization reduces the rate of sodium influx; and (3) loss of P waves, ST segment depression, and eventual sine-wave pattern (at K+ >8 mEq/L) represent near-complete depolarization and imminent cardiac collapse. The mechanism of arrhythmias includes both re-entry (from non-uniform conduction delays) and enhanced automaticity of ectopic pacemakers. Critically, the severity of cardiac toxicity depends not only on absolute potassium concentration but also on the rate of rise—hyperkalemia developing over hours causes more severe cardiac effects than the same level reached gradually.

• Chronic Kidney Disease and Acute Kidney Injury: CKD stage 4-5 (GFR <15 mL/min) represents the most common underlying predisposition. AKI from any cause (sepsis, ischemia, nephrotoxins, rhabdomyolysis) produces rapid potassium accumulation, particularly oliguric AKI where urine output is severely reduced. The risk escalates dramatically when concurrent medications block aldosterone (ACE-I, ARB, NSAIDs) or inhibit collecting duct potassium secretion.

• RAAS Antagonists (ACE Inhibitors and Angiotensin Receptor Blockers): These agents cause hyperkalemia through multiple mechanisms: (1) reduced aldosterone synthesis (ACE-I/ARB block angiotensin II → aldosterone production), (2) decreased renal perfusion pressure (through efferent arteriole vasodilation) reducing potassium secretion, and (3) direct inhibition of renal potassium handling in the collecting duct. Risk is highest when combined with CKD (GFR <30), NSAIDs, potassium supplements, or spironolactone (potassium-sparing diuretic). Incidence of hyperkalemia with ACE-I monotherapy in CKD is ~2-5% annually, but rises to 10-15% when combined with NSAIDs.

• NSAIDs (Non-Steroidal Anti-Inflammatory Drugs): NSAIDs reduce renal prostaglandin synthesis, which normally maintains renal blood flow and promotes renin release. This leads to: (1) decreased GFR and potassium filtration, (2) suppressed aldosterone production (via reduced renin), and (3) direct effects on collecting duct function. Combined with CKD or ACE-I/ARB use, NSAIDs carry a synergistic hyperkalemic risk. Even short courses of NSAIDs can precipitate life-threatening hyperkalemia in susceptible patients.

• Potassium-Sparing Diuretics (Spironolactone, Amiloride, Triamterene): These agents directly antagonize aldosterone receptors (spironolactone) or block ENaC (amiloride, triamterene), preventing potassium secretion in the collecting duct. While useful in heart failure and cirrhosis, they carry substantial hyperkalemic risk in CKD, AKI, or concurrent RAAS blockade. Spironolactone combined with ACE-I in CKD has caused life-threatening hyperkalemia in multiple case series.

• Trimethoprim and Pentamidine: These antimicrobial agents directly block ENaC in the collecting duct through a mechanism analogous to amiloride, causing hyperkalemia independent of aldosterone status. High-dose trimethoprim (as in high-dose TMP-SMX for Pneumocystis prophylaxis) or prolonged pentamidine are notable offenders. Risk is particularly high in CKD patients.

• Beta-Adrenergic Antagonists (Non-Selective): Propranolol, nadolol, and atenolol (when used in high doses) block β2-adrenergic receptors on skeletal muscle, impairing insulin-mediated and catecholamine-induced cellular potassium uptake. This becomes clinically problematic in patients with concurrent renal insufficiency, diabetes on insulin, or acidosis. Notably, this is a relative contraindication to non-selective beta-blockers in hyperkalemic patients with AKI.

• Diabetic Ketoacidosis (DKA) and Hyperglycemic Hyperosmolar State (HHS): DKA produces severe hyperkalemia through dual mechanisms: osmotic shifts (from hyperglycemia) and insulin deficiency impair potassium uptake into cells. Paradoxically, despite total body potassium depletion (losses of 300-1000 mEq from osmotic diuresis and vomiting), serum potassium is typically elevated. With insulin treatment, potassium rapidly re-enters cells, causing hypokalemia within hours—a critical monitoring point.

• Tumor Lysis Syndrome (TLS): Acute release of intracellular contents from rapidly dividing malignancies (especially acute leukemias and high-grade lymphomas) floods the serum with potassium, phosphate, and uric acid. Potassium levels can exceed 8-9 mEq/L within hours. This is a medical emergency requiring aggressive hydration and acute management strategies.

• Rhabdomyolysis: Muscle breakdown from crush injury, statin-induced myopathy, severe exertion, malignant hyperthermia, or statins releases massive amounts of myoglobin, potassium, and phosphate. Associated AKI compounds the problem. Potassium levels >7 mEq/L are common.

• Massive Hemolysis: Transfusion reactions, G6PD deficiency, autoimmune hemolytic anemia, or microangiopathic hemolytic anemias release intracellular potassium. Stored blood products used for massive transfusion contain high potassium (~40-50 mEq/L per unit).

• Type 4 Renal Tubular Acidosis (Hyperkalemic RTA): This entity represents impaired distal acidification and potassium secretion, categorized as Type IV RTA. It occurs in primary hypoaldosteronism (congenital adrenal hyperplasia, bilateral adrenalectomy), secondary hypoaldosteronism (DM with hyporeninemic hypoaldosteronism, NSAIDs, ACE-I/ARB), or aldosterone resistance (kidney disease itself, NSAIDs, amiloride). Presents with mild hyperkalemia (5.5-6.5 mEq/L), hyperchloremic metabolic acidosis, and low/low-normal plasma renin activity.

• Addison's Disease (Primary Adrenal Insufficiency): Complete loss of aldosterone and cortisol production causes life-threatening hyperkalemia, hyponatremia, and hypotension. Acute adrenal crisis presents with hyperkalemia often >6-7 mEq/L. Also consider secondary adrenal insufficiency from pituitary disease, though aldosterone is often partially preserved.

• Medications Reducing Aldosterone or Blocking Its Action: Beyond those mentioned, NSAIDs, COX-2 inhibitors, heparin (suppresses aldosterone synthesis), lithium, and tacrolimus/cyclosporine (immunosuppressants that impair potassium secretion) all contribute.

• Acidosis (Non-Anion Gap): Mineral acidosis (hyperchloremic metabolic acidosis from HCl administration, diarrhea with bicarbonate loss, or renal tubular acidosis) directly impairs renal potassium secretion and promotes transcellular shift. Organic acidosis (lactic acidosis, ketoacidosis) has complex effects—see DKA above.

• Exercise and Muscle Injury: Intense exercise releases potassium from muscle; in patients with renal insufficiency or medications impairing renal excretion, this can precipitate symptomatic hyperkalemia. Exertion-induced rhabdomyolysis is particularly dangerous.

• Potassium Supplementation and Dietary Excess: While healthy kidneys tolerate excess potassium, patients with CKD, RAAS blockade, or aldosterone deficiency cannot. Salt substitutes (KCl-based), potassium supplements, and high-potassium diets (promoted for CKD management ironically) are common culprits.

• Cardiac Manifestations (Most Dangerous and Life-Threatening): Cardiac effects dominate the clinical picture and drive urgency of treatment. Peaked (or "tented") T waves are the earliest ECG change (K+ typically 5.5-6.5 mEq/L), appearing as symmetrical, narrow-based T waves with increased amplitude, best seen in precordial leads V2-V4. Patients are typically asymptomatic at this stage. As potassium rises further, PR interval prolongation (slowed AV nodal conduction), QRS complex widening (slowed ventricular conduction), and QT prolongation appear. In severe hyperkalemia (K+ >7 mEq/L), P waves disappear entirely, the ST segment becomes depressed, and the ECG may progress to a characteristic "sine wave" pattern (fusion of QRS, ST, and T waves into a smooth undulation), representing imminent ventricular fibrillation. Arrhythmias include sinus bradycardia (from conduction slowing), atrial fibrillation or flutter, ventricular premature beats, ventricular tachycardia, and ultimately ventricular fibrillation or asystole. Importantly, the correlation between ECG changes and potassium level is imperfect; a patient may progress from peaked T waves to sine wave pattern within minutes, or ECG changes may be absent despite dangerously high potassium. Patients may report palpitations or syncope from arrhythmias, or present in cardiac arrest.

• Neuromuscular Manifestations: Hyperkalemia impairs neuromuscular transmission through altered action potential generation in skeletal muscle. Patients report **generalized

Step 1 — confirm the value is real

• Repeat the serum potassium before acting on an isolated result in an asymptomatic patient with a normal ECG. Pseudohyperkalemia arises from potassium leaking out of cells after the draw: hemolyzed specimen, prolonged tourniquet time or fist clenching, small-bore needle, or delayed processing.
• Marked leukocytosis or thrombocytosis (chronic lymphocytic leukemia, essential thrombocythemia) releases potassium during in-vitro clot formation; the clue is a normal plasma potassium drawn in a heparinized tube alongside a high serum value, with no ECG changes.

Step 2 — the test that changes management

• 12-lead ECG immediately. It is not a confirmatory test for the potassium level but is the decisive triage study, since cardiotoxicity — not the number — dictates urgency. Expect peaked, narrow-based T waves around 5.5–6.5 mEq/L; PR prolongation and QRS widening around 6.5–7.5 mEq/L; loss of P waves, bradyarrhythmia, and the sine-wave pattern above roughly 8 mEq/L. A normal ECG never excludes dangerous hyperkalemia.

Step 3 — establish the mechanism

• Basic metabolic panel for creatinine/eGFR, glucose, and bicarbonate (renal failure, DKA, non-anion-gap acidosis of type 4 RTA), plus CBC.
• Cell-lysis panel when the history suggests it: CK for rhabdomyolysis; uric acid, phosphate, LDH, and calcium for tumor lysis syndrome; haptoglobin and smear for hemolysis.
• Blood gas if acidosis is suspected, and a careful medication review (RAAS blockers, MRAs, NSAIDs, trimethoprim, heparin, calcineurin inhibitors, salt substitutes).
• Urine potassium and urine potassium-to-creatinine ratio distinguish renal from extrarenal causes; a low urinary potassium in the face of hyperkalemia points to impaired secretion. The transtubular potassium gradient (TTKG) appears in older texts but has largely been abandoned because its assumptions about medullary urea and water handling do not hold.
• Plasma renin activity, aldosterone, and morning cortisol/cosyntropin stimulation when hypoaldosteronism or primary adrenal insufficiency is suspected.

1. Membrane stabilization (first, whenever ECG changes or K+ is severely elevated)

• IV calcium: calcium gluconate 1 g (10 mL of 10%) IV over several minutes, repeated if ECG changes persist; calcium chloride only through a central line because of tissue necrosis with extravasation. It raises the depolarization threshold and restores the gradient between resting potential and threshold — it does not lower potassium, and its effect lasts only about 30–60 minutes.
• Older teaching listed digoxin toxicity as an absolute contraindication (stone heart); current practice favors giving calcium while treating with digoxin-specific antibody Fab fragments, which is the definitive therapy.

2. Intracellular shift (minutes to an hour)

• Insulin plus dextrose: regular insulin IV with concurrent dextrose (omit dextrose only if the patient is already hyperglycemic). Insulin drives the Na-K-ATPase; reduce the insulin dose in advanced CKD and recheck glucose serially.
• Beta-2 agonist: high-dose nebulized albuterol, additive to insulin via β2-stimulated Na-K-ATPase activity. Not reliable as monotherapy — a subset of patients does not respond.
• Sodium bicarbonate: reserve for concurrent metabolic acidosis; it is slow and unreliable as an acute potassium-lowering agent. Never infuse in the same line as calcium (precipitation).

3. Elimination from the body (the only step that reduces total body potassium)

• Loop diuretic (furosemide) with volume repletion if urine output is preserved.
• Gastrointestinal binders: sodium zirconium cyclosilicate and patiromer are the modern agents and are the ones KDIGO endorses to permit continuation of RAAS inhibitors in CKD and heart failure. Sodium polystyrene sulfonate (Kayexalate) is slow, of questionable efficacy, and carries an FDA warning for colonic necrosis — it is not emergency therapy.
• Hemodialysis is definitive for refractory hyperkalemia, oliguric AKI, ESRD, or ongoing potassium release (rhabdomyolysis, tumor lysis).

Complications of the disease

• Ventricular fibrillation, pulseless VT, PEA, or asystole — emergency. Non-uniform conduction slowing creates re-entry while partial depolarization inactivates sodium channels. The warning sign is a widening QRS or the sine-wave pattern; treat as cardiac arrest with ACLS plus IV calcium, insulin/dextrose, and emergent dialysis.
• Bradyarrhythmia and high-grade AV block — emergency. Signaled by PR prolongation then loss of P waves; hyperkalemic bradycardia is often refractory to atropine, and calcium plus shifting therapy is the answer rather than pacing alone.
• Ascending flaccid paralysis with respiratory muscle weakness — sustained depolarization inactivates skeletal muscle sodium channels. Signaled by progressive lower-extremity weakness with preserved sensation and, ominously, a falling vital capacity.
• Progressive hyperkalemia from ongoing lysis in rhabdomyolysis or tumor lysis syndrome, where potassium rebounds within hours of any shifting therapy.

Complications of treatment

• Insulin-induced hypoglycemia — the most common iatrogenic harm, and delayed in CKD because insulin clearance is renal. Monitor glucose for several hours after the dose, not just once.
• Rebound hyperkalemia as the calcium and shifting effects wear off, because neither removes potassium from the body — the reason a definitive elimination strategy must be started concurrently.
• Overshoot hypokalemia in DKA, where total body potassium is depleted despite a high serum value; insulin can drop potassium precipitously and provoke arrhythmia.
• Colonic necrosis from sodium polystyrene sulfonate, especially with sorbitol or in postoperative/ileus patients — emergency, heralded by abdominal pain, distension, or bloody stool.
• Volume overload, hypernatremia, and metabolic alkalosis from sodium bicarbonate; edema from the sodium load of sodium zirconium cyclosilicate.
• Drug–binder interactions and hypomagnesemia with patiromer; separate other oral medications in time.
• Tissue necrosis from calcium chloride extravasation, and intradialytic hypotension with post-dialysis rebound as potassium re-equilibrates from the intracellular compartment.

• The single best next step in any hyperkalemia stem is the 12-lead ECG. If ECG changes are present, the next step is IV calcium gluconate — before insulin, before albuterol, before dialysis.
• Calcium stabilizes but does not lower. Insulin/dextrose and albuterol shift potassium intracellularly but also do not remove it. Only diuretics, GI binders, and dialysis reduce total body potassium. Examiners love the distinction between "stabilize, shift, and eliminate."
• Kayexalate is the classic distractor in an acute stem with a sine-wave ECG. Sodium polystyrene sulfonate is slow, of doubtful efficacy, and carries an FDA colonic-necrosis warning; modern binders (patiromer, sodium zirconium cyclosilicate) are for subacute and chronic control, chiefly to allow RAAS inhibitors to be continued in CKD and heart failure per KDIGO.
• Pseudohyperkalemia: a high potassium with a completely normal ECG in an asymptomatic patient with marked leukocytosis or thrombocytosis (or a noted hemolyzed sample). Repeat with a plasma specimen rather than treating.
• Succinylcholine is the association most often tested. Upregulation of extrajunctional nicotinic acetylcholine receptors after burns (beyond the first day or so), crush injury, denervation, stroke, spinal cord injury, or prolonged immobility makes depolarizing blockade cause lethal hyperkalemia and arrest. Use a non-depolarizing agent such as rocuronium instead.
• Type 4 RTA is the buzzword answer for mild hyperkalemia plus a hyperchloremic, normal-anion-gap metabolic acidosis in a long-standing diabetic — hyporeninemic hypoaldosteronism.
• Hyperkalemia in acute digoxin poisoning marks severity and predicts mortality; the treatment is digoxin-specific Fab fragments, not simply potassium lowering.
• In DKA, the serum potassium is high but total body potassium is low. Insulin unmasks the deficit — if potassium is below the normal range at presentation, replete potassium before starting insulin.
• The sine wave means imminent arrest. Do not wait for a repeat laboratory value; treat empirically.